Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   43207   clinical trials with a EudraCT protocol, of which   7151   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).


    Phase 1 trials conducted solely in adults and that are not part of an agreed PIP are not public in the EU CTR (refer to European Guidance 2008/C 168/02   Art. 3 par. 2 and   Commission Guideline 2012/C 302/03,   Art. 5) .

    Clinical Trials marked as "Trial now transitioned" were transitioned to the Clinical Trial Regulation 536/2014 and can be further followed in the Clinical Trial Information System  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2021-001644-10
    Sponsor's Protocol Code Number:D5272C00002
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2021-08-12
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2021-001644-10
    A.3Full title of the trial
    A Phase 2 Open-label, Long-term Extension Safety Study of Brazikumab in Participants with Moderately to Severely Active Ulcerative Colitis (EXPEDITION OLE)
    Ensayo de extensión de seguridad abierto a largo plazo, fase II con brazikumab en pacientes con colitis ulcerosa activa de moderada a grave (Expedition OLE)
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Open-label Extension Study of Brazikumab in Ulcerative Colitis
    Ensayo de extensión abierto de brazikumab en la colitis ulcerosa
    A.3.2Name or abbreviated title of the trial where available
    EXPEDITION OLE
    EXPEDITION OLE
    A.4.1Sponsor's protocol code numberD5272C00002
    A.5.4Other Identifiers
    Name:INDNumber:137684
    Name:LegacyNumber:#3151-202-008
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorAstraZeneca AB
    B.1.3.4CountrySweden
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportAstraZeneca AB
    B.4.2CountrySweden
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationAstraZeneca Farmacéutica Spain, S.A.
    B.5.2Functional name of contact pointUnidad de Investigación Clínica
    B.5.3 Address:
    B.5.3.1Street AddressC/ Serrano Galvache, 56; Parque Norte, Edificio Álamo
    B.5.3.2Town/ cityMadrid
    B.5.3.3Post code28033
    B.5.3.4CountrySpain
    B.5.4Telephone number0034900200444
    B.5.6E-mailinformacionEECC-Spain@astrazeneca.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameBrazikumab
    D.3.2Product code MEDI2070
    D.3.4Pharmaceutical form Solution for injection/infusion in pre-filled syringe
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPSubcutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNBRAZIKUMAB
    D.3.9.1CAS number 1610353-18-8
    D.3.9.3Other descriptive nameAnti-Interleukin-23 Immunoglobulin G2 (IgG2) Human Monoclonal Antibody; also referred to as 'MEDI2070'
    D.3.9.4EV Substance CodeSUB188673
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number240
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy Yes
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameBrazikumab
    D.3.2Product code MEDI2070
    D.3.4Pharmaceutical form Solution for injection/infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNBRAZIKUMAB
    D.3.9.1CAS number 1610353-18-8
    D.3.9.3Other descriptive nameAnti-Interleukin-23 Immunoglobulin G2 (IgG2) Human Monoclonal Antibody; also referred to as 'MEDI2070'
    D.3.9.4EV Substance CodeSUB188673
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number1440
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product Yes
    D.3.11.13.1Other medicinal product typefully human IgG2 monoclonal antibody
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Ulcerative Colitis
    Colitis Ulcerosa
    E.1.1.1Medical condition in easily understood language
    Ulcerative Colitis is a type of inflammatory bowel disease that causes the lining of the large intestine (colon) to become inflamed (irritated and swollen) which may cause ulcers and bleeding.
    La colitis ulcerosa es una enfermedad inflamatoria intestinal que provoca inflamación en el revestimiento del intestino grueso con irritación e hinchazón, que puede causar úlceras y hemorragias.
    E.1.1.2Therapeutic area Diseases [C] - Digestive System Diseases [C06]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.1
    E.1.2Level LLT
    E.1.2Classification code 10045365
    E.1.2Term Ulcerative colitis
    E.1.2System Organ Class 100000004856
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To assess the safety of long-term treatment with brazikumab in UC participants who previously completed or discontinued participation due to lack of efficacy after Week 10 in the lead-in Study D5272C00001 (Legacy #3151-201-008)
    Evaluar la seguridad del tratamiento a largo plazo con brazikumab en pacientes con CU que completaron o interrumpieron su participación debido a la falta de eficacia después de la semana 10 en el ensayo D5272C00001
    E.2.2Secondary objectives of the trial
    Not applicable
    No aplicable
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    Male or female participants who:

    1. successfully completed or discontinued participation due to lack of efficacy after Week 10 in the lead-in Study D5272C00001.
    AND
    Meets 1 of the following criteria for successful completion or early termination from Study D5272C00001:
    (a) Participant completed Study D5272C00001, received scheduled study interventions, completed scheduled visits, and completed Week 54 assessments.
    (b) Participant discontinued participation due to lack of efficacy after Week 10 in Study D5272C00001, received scheduled study interventions, and completed Early Termination Visit assessments.
    2. No known history of active TB or latent TB without completion of appropriate intervention.
    3. Male participants willing to minimize the risk of inducing pregnancy for the duration of the clinical study and follow-up period. Nonsterilized men who are sexually active with a female partner of childbearing potential should use condom during treatment and for 18 weeks after the last dose of study intervention
    4. Female participants of childbearing potential must have a negative urine pregnancy test prior to administration of study intervention and must agree to use a highly effective method of birth control (confirmed by the investigator) from randomization throughout the study duration and for at least 18 weeks after last dose of study intervention
    5. Women not of childbearing potential are defined as women who are either permanently sterilized (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy), or who are postmenopausal.
    6. Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.
    7. Written informed consent from the participant has been obtained prior to any study related procedures.
    8. Written documentation has been obtained in accordance with the relevant country and local privacy requirements, where applicable (eg, Written Authorization for Use and Release of Health and Research Study Information [US sites] and written Data Protection consent [EU sites]).
    9. Demonstration of adequate compliance with the study procedures in Study D5272C00001, in the opinion of the investigator and/or sponsor.
    10. Willingness and ability to attend all study visits, comply with the study procedures, and be able to complete the study period.
    11. Participant must be 18 to 80 years of age inclusive, at the time of signing the ICF.

    Complete inclusion criteria are in the study protocol
    Pacientes adultos que:
    1. Finalizaron satisfactoriamente o interrumpieron su participación por falta de eficacia tras la semana 10 en el ensayo D5272C00001.
    Y
    Cumplen 1 de estos criterios:
    (a) El paciente completó el ensayo D5272C00001, recibió el tratamiento en investigación y completó todas las visitas programadas, incluidas las evaluaciones de la semana 54.
    (b) El paciente interrumpió su participación por falta de eficacia tras la semana 10 en el ensayo D5272C00001, recibió el tratamiento en investigación y completó la visita de retirada temprana.
    2. Sin antecedentes de TB activa latente.
    3. Los hombres sexualmente activos con pareja en edad fértil deben utilizar preservativo durante el ensayo y hasta 18 semanas después de la última dosis del tratamiento del ensayo.
    4. Las mujeres en edad fértil con una prueba de embarazo en orina negativa antes de la administración del tratamiento en investigación, deben utilizar un método anticonceptivo altamente eficaz desde la aleatorización y hasta al menos 18 semanas después de la última dosis de tratamiento en investigación.
    5. Mujeres , con esterilización permanente (histerectomía, ovariectomía bilateral o salpingectomía bilateral) o posmenopáusicas.
    6. Capaz de otorgar y firmar un consentimiento informado.
    7. Se ha obtenido el consentimiento informado por escrito del paciente antes de realizar cualquier procedimiento del ensayo.
    8. Se ha obtenido por escrito el consentimiento para la protección de datos personales.
    9. Capacidad para el cumplimiento adecuado de los procedimientos del ensayo D5272C00001 en opinión del investigador y/o el promotor.
    10. Voluntad y capacidad para asistir a todas las visitas del estudio, y cumplir con los procedimientos.
    11. Paciente entre 18 y 80 años, en el momento de firmar el consentimiento informado.

    Los criterios de inclusión completos se describen en el protocolo del ensayo.
    E.4Principal exclusion criteria
    1. Any participant with an unresolved AE from the lead-in study that, in the investigator’s opinion, would limit the participant’s ability to participate in or complete this study. Any unresolved AE related to an infection will require further discussion with the study medical monitor prior to enrollment.
    2. Current diagnosis of fulminant colitis, CD or indeterminate colitis, presence of a fistula consistent with CD, primary sclerosing cholangitis, celiac disease, or toxic megacolon. Bile acid malabsorption and other conditions that may potentially confound assessments must be treated prior to baseline.
    3. Organ or cell-based transplantation with the exception of corneal transplant.
    4. Any other condition or finding that, in the investigator’s or sponsor’s opinion, would either confound proper interpretation of the study or expose a participant to unacceptable risk.
    5. The following are exclusionary with regards to malignancy:
    a) Evidence of intestinal epithelial dysplasia on endoscopy, and this is confirmed on biopsy, the participant.
    b) Any diagnosis of malignancy that requires discontinuation of study intervention from lead-in study.
    c) Any new diagnosis of malignancy after completion of the lead-in study.
    d) Carcinoma in situ of the cervix, with apparent successful curative therapy within 12 months prior to Week 0.
    6. Participant meets criteria for discontinuation of study intervention during prior lead-in study.
    7. Chronic hepatitis B or C infection
    8. Known history of primary immunodeficiency, splenectomy, or any underlying condition that predisposes the participant to infection, including HIV infection.
    9. Prolonged QTcF interval or conditions leading to additional risk for QT prolongation. Participants with electrolyte abnormalities such as hypokalemia and hypomagnesemia that would increase the risk of QT prolongation are to be corrected prior to enrollment.
    10. Clinically significant kidney disease including but not limited to:
    (a) Chronic kidney disease with an estimated glomerular filtration rate of less than 30 ml/min calculated by Modification of Diet in Renal Disease equation.
    11. Participant requires additional immunosuppressive therapy (aside from permitted concomitant medication in the protocol), biological treatment or prohibited treatment
    12. Participant received a prohibited medication during participation in the D5272C00001 study.
    13. Participant received a Bacille Calmette-Guérin vaccination within 12 months of Week 0 or any other live vaccine < 4 weeks prior to Week 0, or is planning to receive any such vaccine over the course of the study.
    14. Participant has received an investigational product after discontinuation from Study D5272C00001 and prior to enrolling in this study or participant is planning to receive an investigational drug (other than study intervention) or investigational device at any time during Study D5272C00002.
    15. Participant who discontinued participation due to lack of efficacy after Week 10 in Study D5272C00001 and did not receive all 3 IV infusions of study interventions scheduled for Week 0 (Day 1), Week 2 (Day 15), and Week 6 (Day 43), and SC at Week 10 (Day 71) in accordance with the protocol for Study D5272C00001.
    16. Participant who discontinued due to lack of efficacy after Week 10 in Study D5272C00001 but currently demonstrates clinical response and/or meets endoscopic Mayo Score of 0 or 1 prior to Week 54 in Study D5272C00001:
    Clinical Response defined as: Reduction in mMS ≥ 2 points from baseline AND ≥ 30% from baseline, AND a decrease in the rectal bleeding score ≥ 1 point from baseline or a score of 0 or 1, in Study D5272C00001.
    Note: Participants are encouraged to remain in the lead-in Study D5272C00001 if the participant is demonstrating evidence of clinical response. Participants should not early terminate that study due to lack of efficacy if this exclusion is met.
    17. Abnormal laboratory results at screening as described in the protocol.
    18. Females who are pregnant, breast feeding, or planning a pregnancy during the study OR females who are of childbearing potential and do not agree to use contraception.
    19. Participant is directly or indirectly involved in the planning and/or conduct and administration of this study as study staff member, or employee of the sponsor, or the participant is a first-degree family member, significant other, or relative residing with one of the above persons involved directly or indirectly in the study; or the participant is enrolled in this study at another clinical study site.
    20. Judgment that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements.
    21. Previous enrollment in the present study.

    Complete exclusion criteria are in the study protocol
    1. Paciente con un AA no resuelto del ensayo D5272C00001 que, en opinión del investigador, limitaría su capacidad para participar en elensayo. Un AA no resuelto relacionado con una infección requerirá consulta con el monitor médico del ensayo antes de la inclusión.
    2. Diagnóstico actual de colitis fulminante, EC o colitis indeterminada, presencia de fístula compatible con EC, colangitis esclerosante primaria, enfermedad celíaca o megacolon tóxico, malabsorción de ácidos biliares y otras afecciones que puedan confundir las evaluaciones deben tratarse antes de la inclusión.
    3. Trasplante de órganos o células, excepto trasplantes de córnea.
    4. Cualquier otra afección que, en opinión del investigador o promotor, pueda confundir la interpretación del ensayo o exponer la seguridad del paciente.
    5. Con respecto a neoplasias malignas son excluyentes: a) Indicios de displasia epitelial intestinal en la endoscopia confirmado por bipsia.
    b) Un diagnóstico de neoplasia maligna que requiera la interrupción del tratamiento del ensayoD5272C00001.
    c) Un nuevo diagnóstico de neoplasia maligna tras la finalización del ensayo D5272C00001.
    d) Carcinoma in situ del cuello uterino, con tratamiento curativo satisfactorio evidente en los 12 meses anteriores a la semana 0.
    6. Paciente que cumple los criterios de interrupción del tratamiento del ensayo D5272C00001.
    7. Infección crónica por hepatitis B o C
    8. Antecedentes conocidos de inmunodeficiencia primaria, esplenectomía o afección subyacente que predisponga al paciente a una infección, incluida VIH.
    9. Intervalo QTcF prolongado o riesgo de prolongación del intervalo QT. Las anomalías electrolíticas como hipopotasemia e hipomagnesemia que aumentarían el riesgo de prolongación del intervalo QT deben corregirse antes de la inclusión.
    10. Enfermedad renal clínicamente significativa que incluye:
    (a) Tasa de filtración glomerular <30 ml/min calculada mediante la ecuación de modificación de la dieta en la enfermedad renal.
    11. Paciente que requiere tratamiento inmunodepresor (aparte de la medicación concomitante permitida en el protocolo), tratamiento biológico o tratamiento prohibido.
    12. Paciente que recibió medicación prohibida durante su participación en el ensayo D5272C00001.
    13. El paciente recibió una vacuna contra el bacilo de Calmette-Guérin 12 meses antes de la semana 0 o cualquier otra vacuna viva <4 semanas antes de la semana 0, o tiene previsto recibir dicha vacuna durante el transcurso del estudio.
    14. El paciente ha recibido un medicamento en investigación tras la interrupción del ensayo D5272C00001 y antes de la inclusión en este ensayo, o tiene previsto recibir tratamiento en investigación o producto sanitario en investigación durante el ensayo D5272C00002.
    15. Paciente que interrumpió su participación debido a la falta de eficacia tras la semana 10 en el ensayo D5272C00001 y no recibió las 3 infusiones i.v. del tratamiento en investigación en la semana 0 (día 1), semana 2 (día 15) y semana 6 (día 43), y s.c. en la semana 10 (día 71) de acuerdo con el protocolo del ensayo D5272C00001.
    16. Paciente que interrumpió el tratamiento en investigación por falta de eficacia tras la semana 10 en el ensayo D5272C00001 que muestra respuesta clínica y/o cumple subíndice endoscópico Mayo0-1 antes de la semana 54 en el ensayo D5272C00001:
    La respuesta clínica se define como: Reducción de la mMS ≥2 puntos desde el inicio Y ≥30 % desde el inicio Y disminución del subíndice de hemorragia rectal ≥1 punto desde el inicio o puntuación de 0-1, en el ensayo D5272C00001. Se anima a los pacientes a permanecer en el ensayoD5272C00001 si está demostrando indicios de respuesta clínica. Los pacientes no deben retirarse prematuramente por falta de eficacia si se cumple esta exclusión.
    17. Resultados analíticos anormales en la selección según se describe en el protocolo.
    18. Mujeres embarazadas, en periodo de lactancia o que tienen previsto quedarse embarazadas durante el estudio O bien mujeres en edad fértil que no acepten utilizar métodos anticonceptivos.
    19. El paciente participa directa o indirectamente en la planificación, realización y/o administración como personal del ensayo, miembro del promotor, o es pariente de primer grado, pareja, o familiar que reside con personas implicadas directa o indirectamente en el ensayo; o está participando en otro centro del ensayo clínico.
    20. Si el investigador considera que el paciente no debería participar si es improbable que cumpla con los requisitos del ensayo.
    21. Inclusión previa en el presente ensayo.

    Los criterios de exclusión completos se encuentran en el protocolo del ensayo.
    E.5 End points
    E.5.1Primary end point(s)
    - AEs
    - Clinical laboratory values
    - Vital signs
    -Physical exams
    - ECGs
    - AA
    - Valores analíticos clínicos
    - Constantes vitales
    - Exploraciones físicas
    - Electrocardiogramas
    E.5.1.1Timepoint(s) of evaluation of this end point
    Across the 52-week treatment period for each primary endpoints
    A lo largo del periodo de tratamiento de 52 semanas para cada criterio de valoración principal.
    E.5.2Secondary end point(s)
    Not applicable
    No aplicable
    E.5.2.1Timepoint(s) of evaluation of this end point
    Not applicable
    No aplicable
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic Yes
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other Yes
    E.8.1.7.1Other trial design description
    Ensayo de extensión
    Extension study
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned6
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA80
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Austria
    Canada
    Czechia
    France
    Germany
    Hungary
    India
    Israel
    Italy
    Japan
    Korea, Republic of
    Poland
    Russian Federation
    South Africa
    Spain
    Taiwan
    Ukraine
    United Kingdom
    United States
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years3
    E.8.9.1In the Member State concerned months6
    E.8.9.1In the Member State concerned days10
    E.8.9.2In all countries concerned by the trial years4
    E.8.9.2In all countries concerned by the trial months9
    E.8.9.2In all countries concerned by the trial days5
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 170
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 10
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state8
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 90
    F.4.2.2In the whole clinical trial 180
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    None
    Ninguno
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2021-11-30
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2021-09-15
    P. End of Trial
    P.End of Trial StatusOngoing
    For support, visit the EMA Service Desk , log in using your EMA account and open a ticket specifying "EU CTR" in your request.
    If you do not have an account, please visit the EMA Account management page page click on "Create an EMA account" and follow the instructions.
    The status of studies in GB is no longer updated from 1.1.2021
    For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2023 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA